Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 13125 mg; potassium chloride, quantity: 46.6 mg; sodium chloride, quantity: 350.7 mg; sodium bicarbonate, quantity: 178.5 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 6562.5 mg; sodium bicarbonate, quantity: 89.25 mg; potassium chloride, quantity: 23.3 mg; sodium chloride, quantity: 175.35 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation and treatment of chronic constipation in adults and children aged 2 years and older. for resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum, or the rectum and colon, confirmed by physical examination of abdomen and rectum, in adults and children 2 years and older. for prevention of recurrence of faecal impaction in children aged 2 years and older. use in children 2 years and older should be limited to 12 weeks except under medical supervision.

Australia - English - Department of Health (Therapeutic Goods Administration)

key pharmaceuticals pty ltd - macrogol 3350, quantity: 1 g/g - powder - excipient ingredients: - for effective relief from constipation and treatment of chronic constipation. softens stools.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - temozolomide 100mg;   - capsule - 100 mg - active: temozolomide 100mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - temozolomide 140mg;   - capsule - 140 mg - active: temozolomide 140mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - temozolomide 180mg;   - capsule - 180 mg - active: temozolomide 180mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - temozolomide 20mg;   - capsule - 20 mg - active: temozolomide 20mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - temozolomide 250mg;   - capsule - 250 mg - active: temozolomide 250mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - temozolomide 5mg;   - capsule - 5 mg - active: temozolomide 5mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - somatropin -